首页 > 市场调查报告书 > 製药

市场调查报告书

商品编码

1140739

全球药用辅料市场-2022-2029

Global Pharmaceutical Excipients Market - 2022-2029

出版日期: 2022年10月20日 | 出版商:

DataM Intelligence | 英文 170 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

对仿製药的需求增加是市场增长的驱动力。

在过去十年中，仿製药行业取得了令人难以置信的连胜，公司获得了高于平均水平的股东回报。仿製药是指具有相同用法、剂量、重量、给药途径和成本的品牌药的仿製药。据印度品牌资产基金会称，印度是全球製药行业的新兴参与者。印度是世界领先的仿製药供应国之一，占全球销售额的20%，供应全球约60%的免疫需求。印度製药业在全球的价值约为 420 亿美元，并且还在持续增长。例如，2021 年 8 月的印度医药市场从 2020 年 7 月的 13.7% 年增长率为 17.7%。就处方药出口量而言，它也位居世界第12位。印度药品出口到全球200多个国家，美国是一个重要市场。仿製药占全球出口的20%，使其成为全球最大的仿製药供应商。印度2010财年药品和药品的出口额为246亿美元，2021财年为244.4亿美元。

然而，监管障碍限制了新辅料的开发。缺乏生产和许可辅料的独立规则阻碍了涉及新型辅料的研发项目。在当前的监管环境下，如果一项新药申请（NDA）失败，则赋形剂已经失败，即使失败不是因为赋形剂。此外，来自失败辅料的临床试验的证据是无益的。因此，药品生产企业和辅料生产企业遭受重大经济损失。製造符合法规要求的新辅料所需的成本和时间对于製造商来说是高得令人望而却步的，并降低了接受新辅料的可能性。

地理渗透。

在预测期内，欧洲是主要地区。

该研究按地区分析了全球市场的药用辅料市场，包括北美、欧洲、亚太地区、南美、中东和非洲。

欧洲将在 2021 年主导全球药用辅料市场。由于各种具有巨大製造能力的製药巨头的出现，该地区的辅料消费处于高水平。对新型辅料不断增长的需求也受到对优质药物、仿製药和生物仿製药的日益依赖的推动。此外，预计欧洲在预测期内的价值将出现显着增长。

由于其庞大的人口基数，尤其是在印度和中国，预计亚太药用辅料市场在预测期内将出现快速增长。此外，新兴国家医疗设施的扩张、大量仿製药製造商、政府举措和专业团体的增加等预计将推动亚太地区药用辅料市场的增长。

竞争格局。

由于大型医疗公司的存在，药用辅料市场是一个竞争激烈的市场。为全球市场增长做出贡献的领先药用辅料製造商有 Dupont des Nemours、Roquette-Pheles、Ashland World Holdings Ltd.、BASF SE、Evonik Industries AG、Associated British Foods plc、Archer-Daniel-Midland Corporation、Lubrizol Corporation、Kuroda国际、Innophos Holdings 等。领先公司正在为药用辅料市场的全球增长采取新产品发布和扩张战略。2022 年 4 月，Ashland将扩大与 Univer 的药物成分分销协议。该协议将为 Univer Solutions 在巴西和墨西哥的客户提供亚甚兰固体剂型粘合剂和崩解剂、缓释药物基质形成剂以及常规和缓释固体剂型包衣的使用权。该协议结合了两家专注于可持续发展的公司的优势和服务，这些公司在拉丁美洲和全球提供基于科学的製药解决方案。2021 年 12 月，全球植物成分领导者和天然药用辅料的领先供应商 Roquette 宣布计划在美国开设新的创新中心，以进一步推进处方药。2022 年 2 月，Azeris 扩大了与领先的药用辅料供应商 Roquette 的合作伙伴关係，在印度推出了一系列药用纤维素产品，加强了其在印度的製药业务。该合作伙伴关係扩展了 Roquette 的全面产品组合，包括微晶纤维素 (MCC) 和交联羧甲基纤维素钠 (CCS) 产品。

COVID-19 的影响将对全球药用辅料市场产生积极影响。

随着与 COVID-19 无关的医疗保健设施继续以正常速度运行，预计全球对药用辅料的需求将在整个 COVID-19 流行病的出现期间增加。在当前的 COVID-19 大流行之后，药用辅料市场预计将增长。市场进入者必须专注于解决 COVID-19 大流行带来的供应链挑战并设计适当的解决方案。

全球药用辅料市场报告提供了大约 61 个市场数据表、57 个数字和 170 页的结构。

Market Overview

Pharmaceutical Excipients Market was valued at USD XX million in 2021. It is forecasted to reach USD XX million by 2029, growing at a CAGR of 5.5 % during the forecast period (2022-2029).

Pharmaceutical excipients are harmless compounds used in the production process used in the dosage form of a pharmaceutical product but are not pharmacologically active components. Excipients are often used in drug formulation to provide long-term stabilization, bulk up stable formulations, and aid absorption. They often improve the product's overall protection or reliability during storage or use. Pharmaceutical excipients are being driven by factors such as the growing pharmaceutical industry, advances in functional excipients, the introduction of orphan drugs, and the penetration of biopharmaceuticals.

Market Dynamics: The rise in demand for generic drugs drives market growth.

Over the last decade, the generics sector has had a phenomenal streak, with businesses earning above-average shareholder returns. Generic products are generic versions of branded drugs with the same dosage type, weight, route of delivery, and cost. According to the India Brand Equity Foundation, India is a rising player in the global pharmaceutical sector. India is one of the world's leading generic medication suppliers, accounting for 20% of volume worldwide and supplying about 60% of the global vaccination demand. The Indian pharmaceutical sector is continuously growing at around US$ 42 billion worldwide. For instance, in August 2021, the Indian pharmaceutical market increased by 17.7% annually, up from 13.7% in July 2020. It is the 12th largest exporter of medical goods in the world. Indian drugs are exported to more than 200 countries worldwide, with the US being the key market. Generic drugs account for 20% of the global export volume, making the country the largest provider of generic medicines globally. Indian drug & pharmaceutical exports stood at US$ 24.60 billion in FY22 and US$ 24.44 billion in FY21.

However, regulatory hurdles restrict the development of novel pharmaceutical excipients. The lack of independent rules for excipient manufacturing and clearance is deterring R&D projects involving novel excipients. In the current regulatory environment, if a new drug application (NDA) fails, the excipient still fails, even if the failure is not attributed to the excipient. Furthermore, the evidence from the unsuccessful excipient's clinical trials was useless. The drug and the excipient maker suffer significant financial losses due to this. The cost and time required to produce novel excipients when adhering to regulatory requirements are prohibitively expensive for manufacturers, reducing the likelihood of a novel excipient being accepted.

Market Segmentation: The organic segment is projected to be the dominant segment in the market during the forecast period.

Based on the Product, the pharmaceutical excipients market has been classified into Organic, Inorganic and Others.

Organic dominated the global market in 2019, owing to the wide usage of organic in the majority of pharmaceutical formulations available in the pharmaceutical market. At the same time, organic is expected to present considerable growth in the near future. Natural excipients are primarily used in oral formulations as binders and fillers, which aid segmental growth during the forecast period.

Pharmaceutical excipients are segmented based on formulation, which includes oral, parenteral, topical and others.

The oral segment held a significant market share in the forecast period as oral formulations are the most common route of drug delivery, which supports the segment growth during the forecast period. Moreover, the Topical is expected to project a considerable CAGR during the forecast period. Strong assimilation of topical excipients with liquid APIs and improved patient compliance due to sensorial effects drive this segment's development.

Geographical Penetration: Europe is the dominating region during the forecast period.

Based on geography, the study analyzes the pharmaceutical excipients market in the global market, including North America, Europe, Asia-Pacific, South America, and the Middle East & Africa.

Europe held a dominant position in the global pharmaceutical excipients market in 2021. Excipient consumption in the region is high due to the emergence of various pharmaceutical behemoths with massive manufacturing capacities. The increased demand for novel excipients is also due to the increasing reliance on superior pharmaceutical drugs, generics, and biosimilars. Moreover, Europe is expected to represent significant growth in terms of value during the forecast period.

The pharmaceutical excipients market for the Asia Pacific is expected to observe rapid growth over the forecast period, backed by the large population base, especially in India and China. Moreover, the developing healthcare facilities, large number of generic manufacturers and rise in government initiatives and specialist communities are expected to augment the growth of the Asia Pacific pharmaceutical excipients market.

Competitive Landscape:

The Pharmaceutical Excipients market is highly competitive, owing to the presence of big medical companies. The key Pharmaceutical Excipients players which are contributing to the growth of the global market include DuPont de Nemours Inc, Roquette Feres, Ashland Global Holdings Inc.., BASF SE., Evonik Industries AG., Associated British Foods plc, Archer Daniels Midland Company, Lubrizol Corporation, Croda International, Innophos Holdings, among others. The major players are adopting new Product launches and expansion strategies for global growth in the Pharmaceutical Excipients market. In April 2022, Ashland expands its distribution deal with Univar for pharma ingredients. Through this agreement, Univar Solutions customers in Brazil and Mexico have access to Ashland's binders and disintegrants for solid dosage forms, matrix formers for modulated release drugs and coatings for regular and modulated release solid dosage forms. This agreement combines the strengths and offerings of two sustainability-focused companies delivering science-based pharmaceutical solutions in Latin America and globally. In December 2021, Roquette, a global leader in plant-based ingredients and a leading provider of naturally-derived pharmaceutical excipients, announced its plan to open a new Innovation Center in the US to further the advancement of prescription drugs. In February 2022, Azelis strengthened its pharmaceutical presence in India by expanding its partnership with Roquette, a leading provider of pharmaceutical excipients, to distribute its pharmaceutical cellulose product range in India. The company expanded its comprehensive product portfolio through this partnership by including Roquette's Microcrystalline Cellulose (MCC) and Croscarmellose Sodium (CCS) products.

COVID-19 Impact: Positive impact on the global pharmaceutical excipients market.

The growth of global demand for pharmaceutical excipients is projected to increase throughout the emergence of the COVID-19 pandemic as non-COVID-related healthcare facilities continue to run at a regular pace. The market for pharmaceutical excipients is expected to grow in the wake of the current COVID-19 pandemic. Market participants must concentrate on solving the supply chain issues raised by the COVID-19 pandemic and designing appropriate solutions to resolve them.

The global pharmaceutical excipients market report would provide an access to approximately 61 market data tables, 57 figures and 170 pages

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

3.1. Market Snippet by Product
3.2. Market Snippet by Functionality
3.3. Market Snippet by Formulation
3.4. Market Snippet by Region

4. Market Dynamics

4.1. Market Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Rise in demand for Generic Drugs
  - 4.1.1.2. Increasing Chronic condition
- 4.1.2. Restraints:
  - 4.1.2.1. Regulatory hurdles restricting the development of novel pharmaceutical excipients
- 4.1.3. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Value Chain Analysis
5.4. PEST Analysis
5.5. Pricing Analysis
5.6. Regulatory Analysis
5.7. Reimbursement Analysis
5.8. Unmet Needs
5.9. Patent Trends

6. COVID-19 Analysis

6.1. Analysis of Covid-19 on the Market
- 6.1.1. Before COVID-19 Market Scenario
- 6.1.2. Present COVID-19 Market Scenario
- 6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. By Product

7.1. Introduction
7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Segment
7.3. Market Attractiveness Index, By Product Segment
- 7.3.1. Organic*
  - 7.3.1.1. Introduction
  - 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
- 7.3.2. Inorganic
- 7.3.3. Other

8. By Functionality

8.1. Introduction
8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Functionality Segment
8.3. Market Attractiveness Index, By Functionality Segment
- 8.3.1. Fillers*
  - 8.3.1.1. Introduction
  - 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
- 8.3.2. Diluents
- 8.3.3. Coatings
- 8.3.4. Disintegrants
- 8.3.5. Others

9. By Formulation

9.1. Introduction
9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Formulation Segment
9.3. Market Attractiveness Index, By Formulation Segment
- 9.3.1. Oral*
  - 9.3.1.1. Introduction
  - 9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
- 9.3.2. Parenteral
- 9.3.3. Topical
- 9.3.4. Others

10. By Region

10.1. Introduction
10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
10.3. Market Attractiveness Index, By Region
10.4. North America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
- 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Functionality
- 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Formulation
- 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 10.4.6.1. U.S.
  - 10.4.6.2. Canada
  - 10.4.6.3. Mexico
10.5. Europe
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
- 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Functionality
- 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Formulation
- 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 10.5.6.1. Germany
  - 10.5.6.2. U.K.
  - 10.5.6.3. France
  - 10.5.6.4. Italy
  - 10.5.6.5. Spain
  - 10.5.6.6. Rest of Europe
10.6. South America
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
- 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Functionality
- 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Formulation
- 10.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 10.6.6.1. Brazil
  - 10.6.6.2. Argentina
  - 10.6.6.3. Rest of South America
10.7. Asia Pacific
- 10.7.1. Introduction
- 10.7.2. Key Region-Specific Dynamics
- 10.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
- 10.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Functionality
- 10.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Formulation
- 10.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 10.7.6.1. China
  - 10.7.6.2. India
  - 10.7.6.3. Japan
  - 10.7.6.4. Australia
  - 10.7.6.5. Rest of Asia Pacific
10.8. Middle East and Africa
- 10.8.1. Introduction
- 10.8.2. Key Region-Specific Dynamics
- 10.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
- 10.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Functionality
- 10.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Formulation
- 10.8.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

11. Competitive Landscape

11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis

12. Company Profiles

12.1. DuPont de Nemours Inc*
- 12.1.1. Company Overview
- 12.1.2. Product Portfolio and Description
- 12.1.3. Key Highlights
- 12.1.4. Financial Overview
12.2. Roquette Feres.
12.3. Ashland Holdings Inc..
12.4. BASF SE.
12.5. Evonik Industries AG.
12.6. Associated British Foods plc
12.7. Archer Daniels Midland Company
12.8. Lubrizol Corporation.
12.9. Croda International
12.10. Innophos Holdings (LIST NOT EXHAUSTIVE)

13. Premium Insights

14. DataM Intelligence

14.1. Appendix
14.2. About Us and Services
14.3. Contact Us

02-2729-4219

+886-2-2729-4219

License/价格

全球药用辅料市场-2022-2029